Investors

Overview

Corporate Profile

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently we are developing our proprietary Chimeric Antigen Receptor (CAR) engineered NK cells (CAR-NK) technology, which we licensed from the laboratories of Drs. Michael Caligiuri and Jianhua Yu at the City of Hope National Medical Center (COH).

Press Releases

CytoImmune Therapeutics Appoints Renowned Oncologist and Immunologist as New Chief Executive Officer

Privately held CytoImmune Therapeutics, Inc. strengthens its team by appointing cell therapy veteran Christina Coughlin, M.D., Ph.D. as CEO LOS ANGELES, Nov. 10, 2021 (GLOBE NEWSWIRE) […]

CytoImmune Not Affected by The Recent Challenges in Allogeneic CAR T Cell Engineering

Pioneering Immunotherapy Platforms for Patient Solutions CytoImmune Therapeutics takes a concerted approach to immunotherapy, combining powerful technologies with potent immune cells to create a cohesive therapeutic […]

CytoImmune Therapeutics Welcomes Aleksey Krylov, Chief Financial Officer

With an experienced Chief Financial Officer on board, the company is continuing to advance its fight against cancer. CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a […]

CytoImmune Therapeutics Announces Appointment of Industry Veteran Douglas E. Williams, Ph.D., to Board of Directors

MONROVIA, Calif., June 15, 2021 /PRNewswire/ -- CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today the […]

CAR NK Cell Therapy Directed Against Pancreatic Cancer

Using donated umbilical cord blood, researchers from City of Hope National Medical Center in Los Angeles created an off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) […]

Events Presentation

CytoImmune will participate in the Stifel 2021 Virtual Healthcare Conference

Register for the Stifel 2021 Virtual Healthcare Conference Speaker Ready Practice Session: Dated: November 15th, 2021 Time: 9:20 AM (ET) {{ vc_btn:title=Register+Now&color=primary&link=url%3Ahttps%253A%252F%252Fwsw.com%252Fwebcast%252Fstifel58%252Fcytoi%252F2293920%7C%7Ctarget%3A%2520_blank%7C&el_class=more-btn }} About CytoImmune Therapeutics, […]

CytoImmune Therapeutics | Wells Fargo Healthcare Conference

Join the CytoImmune Therapeutics | Wells Fargo Healthcare Conference CytoImmune Therapeutics | Wells Fargo Healthcare Conference Session: September, 2021 {{ vc_btn:title=Join+Now&color=primary&link=url%3Ahttps%253A%252F%252Fkvgo.com%252Fwells-fargo%252Fcytoimmune-therapeutics-sept-2021%7C%7Ctarget%3A%2520_blank%7C&el_class=more-btn }} About CytoImmune Therapeutics, Inc. […]

CytoImmune Therapeutics, Inc. CMO Michael Caligiuiri, MD to Present at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, […]

CytoImmune Therapeutics, Inc. President William Rosellini to Present at Upcoming Conferences

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, […]

Press Releases

Events Presentation

CytoImmune will participate in the Stifel 2021 Virtual Healthcare Conference

Register for the Stifel 2021 Virtual Healthcare Conference Speaker Ready Practice Session: Dated: November 15th, 2021 Time: 9:20 AM (ET) {{ vc_btn:title=Register+Now&color=primary&link=url%3Ahttps%253A%252F%252Fwsw.com%252Fwebcast%252Fstifel58%252Fcytoi%252F2293920%7C%7Ctarget%3A%2520_blank%7C&el_class=more-btn }} About CytoImmune Therapeutics, […]

CytoImmune Therapeutics | Wells Fargo Healthcare Conference

Join the CytoImmune Therapeutics | Wells Fargo Healthcare Conference CytoImmune Therapeutics | Wells Fargo Healthcare Conference Session: September, 2021 {{ vc_btn:title=Join+Now&color=primary&link=url%3Ahttps%253A%252F%252Fkvgo.com%252Fwells-fargo%252Fcytoimmune-therapeutics-sept-2021%7C%7Ctarget%3A%2520_blank%7C&el_class=more-btn }} About CytoImmune Therapeutics, Inc. […]

CytoImmune Therapeutics, Inc. CMO Michael Caligiuiri, MD to Present at a KOL Webinar on Human Natural Killer (NK) Cell Immunotherapy

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, […]

CytoImmune Therapeutics, Inc. President William Rosellini to Present at Upcoming Conferences

Monrovia, CA and July 16th, 2021 (GLOBE NEWSWIRE) – CytoImmune Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, […]